Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

Developments in the treatment of SLE and Covid-19 considerations

By Mindo - 04th Jun 2021 | 85 views

Irish Society for Rheumatology Spring Meeting, Virtual, 13 May 2021

Prof Michelle Petri, Professor Division of Rheumatology at Johns Hopkins University, US, closed the ISR Spring Meeting with her presentation providing an overview of modern lupus treatment. Prof Petri is the Director of the Hopkins Lupus Cohort, a longitudinal cohort of morbidity and mortality in systemic lupus erythematosu (SLE) patients and Co-Director of the Hopkins Lupus Pregnancy Centre.

Asserting that “we cannot continue to rely on corticosteroids” in the treatment of lupus given their negative impact, Prof Petri referenced a cohort study by the Toronto Lupus Group, which showed that after 10 years from the date of diagnosis with lupus, 80 per cent of patients in the cohort suffered from permanent organ damage as a result of steroids.

Prof Petri strongly advocates for the use of hydroxychloroquine as a background therapy in all SLE patients. Although it has been found to increase the incidence of retinopathy, the use of OCT ocular imaging can be used to detect this at an early stage, avoiding any loss of visual acuity.

The current use of immunosuppressant drugs in the treatment of lupus is predominantly organ-based, with methotrexate, mycophenolate, leflunomide, and azathioprine noted for different organs. Prof Petri raised some interesting new developments of note. Anifrolumab, which is awaiting US FDA approval, showed a positive BILAG-Based Composite Lupus Assessment response after four weeks, a positive SRI (4) response after eight weeks and a clear benefit for skin with Cutaneous Lupus Erythematosus Disease Area and Severity Index activity increasing at four weeks. Prof Petri observed this in her own patients and noted durable results for skin.

Regarding the ongoing pandemic, Prof Petri also addressed current considerations in light of Covid-19. She advised that prednisone needs to be limited, something she would advise in any case due to the increased risk of cardiovascular events it poses. However, rituximab also needs to be limited, where possible, to avoid any increased risk to the patient. In relation to vaccination, there were fears that the mRNA vaccines may cause lupus flares, but this has not materialised in Prof Petri’s experience.

Further, it was thought that renal transplant literature suggests that patients being administered mycophenolate may not have the expected antibody response to the Covid-19 vaccines. To attempt to address this in her own patients, Prof Petri has held off on the use of the major immunosuppressive medications for one week post vaccination, although success cannot be confirmed at this point.

Leave a Reply

Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read